Subscribe to Newsletter

Content by Stephanie Vine:

Manufacture Facilities

Pfizer to Rebuild Plant Damaged by Tornado

| Stephanie Vine | 3 min read

Both the FDA and Pfizer have released statements in the aftermath of the North Carolina tornado.

Discovery & Development Advanced Medicine

Video: Angela Osborne Discusses the Latest Cell and Gene Industry Trends

| Stephanie Vine

Check out our latest video interview with Angela Osborne who discusses the latest cell and gene industry trends.

Business & Regulation Digital Technologies

The ADHD Video Game – for Adults

| Stephanie Vine | 2 min read

Akili Interactive releases a new version of its ADHD treatment game for adults.

Business & Regulation Business Practice

Enter the Humira Biosimilars

| Stephanie Vine | 2 min read

Humira biosimilars finally launch on the US market

Business & Regulation Business Practice

Drug Pricing Lawsuits Ramp Up

| Stephanie Vine | 5 min read

More pharma stakeholders are launching lawsuits over the US government’s Inflation Reduction Act.

Discovery & Development Drug Discovery

Enhancing CRISPR-Cas9

| Stephanie Vine | 3 min read

Is safeguard sgRNA the key to reducing the off-target effects of gene editing, while increasing its potential applications?

Discovery & Development Drug Discovery

Genetic Science and Sudden Infant Death Syndrome

| Stephanie Vine | 4 min read

The case of Kathleen Folbigg shows how far the field has come, but there are still no medical interventions for sudden infant death syndrome.

Discovery & Development Drug Delivery

Revenge of the ADCs

| Stephanie Vine | 15 min read

Are antibody drug conjugates (ADCs) the breakthrough in cancer treatment? Experts share insights on recent advancements

Business & Regulation Standards & Regulation

MSD Files Lawsuit Against US Government

| Stephanie Vine | 4 min read

MSD describes drug price negotiation program as “sham” and “tantamount to extortion”

Business & Regulation Standards & Regulation

FDA Warning Letters: May 2023 Edition

| Stephanie Vine | 4 min read

Misbranded drugs, unapproved drugs, and companies who don’t know that ophthalmic drugs should be manufactured in a sterile environment…

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register